288 related articles for article (PubMed ID: 1673494)
1. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
[TBL] [Abstract][Full Text] [Related]
2. Liposomal amphotericin B in the treatment of visceral leishmaniasis.
Croft SL; Davidson RN; Thornton EA
J Antimicrob Chemother; 1991 Oct; 28 Suppl B():111-8. PubMed ID: 1778888
[TBL] [Abstract][Full Text] [Related]
3. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
Davidson RN; di Martino L; Gradoni L; Giacchino R; Gaeta GB; Pempinello R; Scotti S; Cascio A; Castagnola E; Maisto A; Gramiccia M; di Caprio D; Wilkinson RJ; Bryceson AD
Clin Infect Dis; 1996 Jun; 22(6):938-43. PubMed ID: 8783690
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.
Karande SC; Boby KF; Lahiri KR; Jain MK; Kshirsagar NA; Gokhale PC; Pandya SK
Trop Doct; 1995 Apr; 25(2):80-1. PubMed ID: 7778200
[No Abstract] [Full Text] [Related]
5. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions.
Seaman J; Boer C; Wilkinson R; de Jong J; de Wilde E; Sondorp E; Davidson R
Clin Infect Dis; 1995 Jul; 21(1):188-93. PubMed ID: 7578729
[TBL] [Abstract][Full Text] [Related]
6. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses.
Banerjee A; De M; Ali N
J Immunol; 2008 Jul; 181(2):1386-98. PubMed ID: 18606693
[TBL] [Abstract][Full Text] [Related]
7. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.
Gangneux JP; Sulahian A; Garin YJ; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 May; 40(5):1214-8. PubMed ID: 8723469
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
Meyerhoff A
Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
[TBL] [Abstract][Full Text] [Related]
9. Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis.
Gupta S; Dube A; Vyas SP
J Drug Target; 2007 Jul; 15(6):437-44. PubMed ID: 17613662
[TBL] [Abstract][Full Text] [Related]
10. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
11. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
12. Exploitation of lectinized lipo-polymerosome encapsulated Amphotericin B to target macrophages for effective chemotherapy of visceral leishmaniasis.
Gupta PK; Asthana S; Jaiswal AK; Kumar V; Verma AK; Shukla P; Dwivedi P; Dube A; Mishra PR
Bioconjug Chem; 2014 Jun; 25(6):1091-102. PubMed ID: 24842628
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis.
Italia JL; Kumar MN; Carter KC
J Biomed Nanotechnol; 2012 Aug; 8(4):695-702. PubMed ID: 22852479
[TBL] [Abstract][Full Text] [Related]
15. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome).
Russo R; Nigro LC; Minniti S; Montineri A; Gradoni L; Caldeira L; Davidson RN
J Infect; 1996 Mar; 32(2):133-7. PubMed ID: 8708370
[TBL] [Abstract][Full Text] [Related]
16. Bioinspired Calcium Phosphate Nanoparticles Featuring as Efficient Carrier and Prompter for Macrophage Intervention in Experimental Leishmaniasis.
Chaurasia M; Singh PK; Jaiswal AK; Kumar A; Pawar VK; Dube A; Paliwal SK; Chourasia MK
Pharm Res; 2016 Nov; 33(11):2617-29. PubMed ID: 27401407
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B: A drug of choice for Visceral Leishmaniasis.
Kumari S; Kumar V; Tiwari RK; Ravidas V; Pandey K; Kumar A
Acta Trop; 2022 Nov; 235():106661. PubMed ID: 35998680
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.
Voak AA; Harris A; Qaiser Z; Croft SL; Seifert K
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630200
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis.
Yardley V; Croft SL
Int J Antimicrob Agents; 2000 Feb; 13(4):243-8. PubMed ID: 10755238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
